Italy’s Doppel Farmaceutici acquired by Trilantic Capital Partners

8 October 2015

Trilantic Capital Partners Europe, a private equity firm focused on mid-market transactions in Europe, says it has completed the acquisition of a 90% shareholding in Doppel Farmaceutici, after obtaining anti-trust approvals.

Doppel is a leading operator in Italy in pharmaceutical research, development, formulation, manufacturing and packaging. The company operates exclusively on behalf of third parties as a contract development and manufacturing organization (CDMO). The investment in Doppel by Trilantic Europe comes as the CDMO pharmaceutical sector is expected to grow significantly in the next five years. Financial details of the investment have not been disclosed.

Trilantic Europe acquired the 90% shareholding in Doppel from a number of Italian entrepreneurs, including Pierluigi Busca who has been a shareholder in Doppel since it was established in 1994. Paolo Lanfranchi remains a shareholder in the company with a 10% holding.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >